Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a public biotechnology company based in Jerusalem, Israel. Oramed develops an orally ingestible capsule for the delivery of protein-based therapies to the blood circulation through the gastro-intestinal (NYSE:GI) pathway, with focus on treatment of diabetes. The Company's business model is based on advancing in-house R&D projects, based on its proprietary drug delivery system, up to mid-stage clinical development, following which the company will aspire to sublicense specific products to major players in the pharmaceutical marketplace.
The company's stock was traded in the OTCQB market until Feb 8, 2013. On Jan 22, 2013, Oramed announced a one for twelve reverse stock split in order to help it meet the qualifications for listing
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|